Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Onvansertib in Combination With Nanoliposomal Irinotecan, Leucovorin, and Fluorouracil for Second-Line Treatment of Patients With Metastatic Pancreatic Ductal Adenocarcinoma

NCT04752696 is registered in ClinicalTrials.gov with Cardiff Oncology as lead sponsor.

NCT NCT04752696
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04752696 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Onvansertib in Combination With Nanoliposomal Irinotecan, Leucovorin, and Fluorouracil for Second-Line Treatment of Patients With Metastatic Pancreatic Ductal Adenocarcinoma
Lead sponsor
Cardiff Oncology
Phase
Phase 2
Overall status
Completed
Start date
May 25, 2021
Completion date
December 24, 2024
Enrollment
41 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic ductal adenocarcinoma